Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
NCT ID: NCT07075510
Last Updated: 2025-10-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
30 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-10-23
Study Completion Date
2032-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to look at the safety, tolerability, and serum concentration of daratumumab administered subcutaneously in the thigh versus the abdomen in patients with plasma cell disorders. Daratumumab is a monoclonal antibody that can attach itself to the CD38 protein on the surface of abnormal plasma cells. Daratumumab can kill the abnormal plasma cells and/or help your immune system find and destroy them. Due to the way daratumumab works, normal cells may also be affected. All reference to the words "study drug" in this consent form will mean Daratumumab.
Daratumumab has been approved by the U.S. Food and Drug Administration (FDA) alone or in combination with other standard of care drugs for treatment of multiple myeloma in both subcutaneous (DARZALEX FASPRO®) and intravenous (DARZALEX®) ways of being delivered. The FDA has also approved the subcutaneous administration of daratumumab combined with other standard of care drugs for patients with light chain (AL) amyloidosis. Subcutaneous means the drug is given by an injection just beneath the skin. Intravenous (IV) means the drug is given as an injection directly into a vein.
Usually when given subcutaneously, the study drug is given by an injection in the abdomen. Having the drug given by subcutaneous injection (underneath the skin of the abdomen) has lessened the IV related side effects and the drug administration by injection is quicker.
However, some patients cannot receive the study drug injections in their abdomen because they find them very painful or have other medical reasons making it difficult to get these injections. The goal of this study is to see if getting the study drug subcutaneously, injected under the skin by a needle, in the patient's upper thigh will have the same results, or better results, as getting the injection in the abdomen. This would therefore, improve patients access to the drug and provide an alternative place to receive the injection of the drug.
This study will take place at University of Maryland Medical Center and there will be about 30 people who will take place in this study here. Dr. Badros is the Sponsor-Investigator of the study. Funding to conduct the study and study drug are being provided by Johnson \& Johnson Innovative Medicine (J\&J IM).
Daratumumab has been approved by the U.S. Food and Drug Administration (FDA) alone or in combination with other standard of care drugs for treatment of multiple myeloma in both subcutaneous (DARZALEX FASPRO®) and intravenous (DARZALEX®) ways of being delivered. The FDA has also approved the subcutaneous administration of daratumumab combined with other standard of care drugs for patients with light chain (AL) amyloidosis. Subcutaneous means the drug is given by an injection just beneath the skin. Intravenous (IV) means the drug is given as an injection directly into a vein.
Usually when given subcutaneously, the study drug is given by an injection in the abdomen. Having the drug given by subcutaneous injection (underneath the skin of the abdomen) has lessened the IV related side effects and the drug administration by injection is quicker.
However, some patients cannot receive the study drug injections in their abdomen because they find them very painful or have other medical reasons making it difficult to get these injections. The goal of this study is to see if getting the study drug subcutaneously, injected under the skin by a needle, in the patient's upper thigh will have the same results, or better results, as getting the injection in the abdomen. This would therefore, improve patients access to the drug and provide an alternative place to receive the injection of the drug.
This study will take place at University of Maryland Medical Center and there will be about 30 people who will take place in this study here. Dr. Badros is the Sponsor-Investigator of the study. Funding to conduct the study and study drug are being provided by Johnson \& Johnson Innovative Medicine (J\&J IM).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The DART Study- Daratumumab Treatment in ITP
NCT04703621
ITP
UNKNOWN
PHASE2
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
NCT00005652
Purpura, Thrombocytopenic, Idiopathic
COMPLETED
PHASE2
Daclizumab to Treat Chronic Immune Thrombocytopenia
NCT00049725
Thrombocytopenia
COMPLETED
PHASE2
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
NCT07063199
Immune Thrombocytopenia
Treatment
RECRUITING
PHASE2
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07297563
Immune Thrombocytopenia
Treatment
RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Plasma Cell Disorder
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ArmA: Treatment with Subcutaneous Daratumumab Administration in the Anterior Upper Thigh
Treatment will be given for 8 weeks. SC Daratumumab will be administered in the thigh weekly for 8 weeks. Patients may receive daratumumab alone or in combination with standard of care regimen
Group Type
EXPERIMENTAL
Daratumumab Injection
Intervention Type
DRUG
Daratumumab Administration in the Anterior Upper Thigh versus the Abdomen
ArmB: Treatment with Subcutaneous Daratumumab Administration in the Abdomen
Treatment will be given for 8 weeks. SC Daratumumab will be administered in the abdomen weekly for 8 weeks. Patients may receive daratumumab alone or in combination with standard of care regimen
Group Type
ACTIVE_COMPARATOR
Daratumumab Injection
Intervention Type
DRUG
Daratumumab Administration in the Anterior Upper Thigh versus the Abdomen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Daratumumab Injection
Daratumumab Administration in the Anterior Upper Thigh versus the Abdomen
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Histologically confirmed diagnosis of MM (newly diagnosed or relapsed) or AL amyloid with planned therapy with daratumumab-based regimen. and has not received daratumumab previously or has received daratumumab \> 6 months prior to planned Cycle 1 Day 1 alone or in combination with other regimens per investigator discretion.
2. Provide signed written informed consent
3. 18 years or older (at the time consent is obtained)
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
5. Participants with a history of autologous stem cell transplant or prior CAR-T cell therapy can enroll on the study provided that:
1. Therapy was \>100 days prior to study enrollment
2. No active infection(s)
6. Adequate organ system function
7. Female participants: Contraceptive use for those participating in clinical studies (men or women) should be consistent with local regulations: A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
1. Is not a woman of childbearing potential (WOCBP) OR
2. Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency, during the intervention period and for at least 12 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The Investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
* A WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention.
* We will review the medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with a new undetected pregnancy.
Non childbearing potential is defined as follows (by other than medical reasons):
* ≥45 years of age and has not had menses for \>1 year
* Patients who have been amenorrhoeic for \<2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range
* Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation.
8. Male participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Male participants are eligible to participate if they agree to the following during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm:
a. Refrain from donating sperm PLUS either:
* Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR
* Must agree to use contraception/barrier and use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a woman of childbearing potential
9. All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0) must be ≤ Grade 1 at the time of enrollment except for alopecia and Grade 2 peripheral neuropathy.
10. Participants are able to comply with visit schedule and agree to weekly visits for 9 weeks
6. Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere participants' safety, obtaining informed consent or compliance with study procedures.
7. Current unstable liver disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. NOTE: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) is acceptable if participant otherwise meets entry criteria.
8. Other malignancies are excluded, except for malignancy from which the patients have been disease-free for more than 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, prostate cancer or in situ cervical or breast cancer that has undergone potentially curative therapy.
9. Chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) \< 50% of predicted normal. Note that FEV1 testing is required for participants suspected of having COPD and participants must be excluded if FEV1 is \< 50% of predicted normal.
10. Moderate or severe persistent asthma within the past 2 years (see Attachment XX), or uncontrolled asthma of any classification. Note that participants who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate.
11. History of cardiovascular disease including any of the following:
1. History of clinically significant untreated arrhythmias, including clinically significant ECG abnormalities including second degree (Mobitz Type II) or third degree atrioventricular (AV) block.
2. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of screening.
3. Class III or IV heart failure as defined by the New York Heart Association functional classification system.
4. Uncontrolled hypertension.
12. Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to daratumumab
13. Active infection requiring treatment.
14. Presence of hepatitis B surface antigen (HbsAg), or hepatitis B core antibody (HbcAb), at screening or within 3 months prior to first dose of study treatment. Note: presence of Hep B surface antibody positivity as the only serologic marker (HBsAb) indicating previous vaccination will not exclude a participant provided that patient has a known history of prior HBV vaccination Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment. NOTE: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. Hepatitis RNA testing is optional and participants with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing.
15. Pregnant or lactating female
2. Provide signed written informed consent
3. 18 years or older (at the time consent is obtained)
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
5. Participants with a history of autologous stem cell transplant or prior CAR-T cell therapy can enroll on the study provided that:
1. Therapy was \>100 days prior to study enrollment
2. No active infection(s)
6. Adequate organ system function
7. Female participants: Contraceptive use for those participating in clinical studies (men or women) should be consistent with local regulations: A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
1. Is not a woman of childbearing potential (WOCBP) OR
2. Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency, during the intervention period and for at least 12 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The Investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
* A WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention.
* We will review the medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with a new undetected pregnancy.
Non childbearing potential is defined as follows (by other than medical reasons):
* ≥45 years of age and has not had menses for \>1 year
* Patients who have been amenorrhoeic for \<2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range
* Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation.
8. Male participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Male participants are eligible to participate if they agree to the following during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm:
a. Refrain from donating sperm PLUS either:
* Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR
* Must agree to use contraception/barrier and use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse with a woman of childbearing potential
9. All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0) must be ≤ Grade 1 at the time of enrollment except for alopecia and Grade 2 peripheral neuropathy.
10. Participants are able to comply with visit schedule and agree to weekly visits for 9 weeks
6. Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere participants' safety, obtaining informed consent or compliance with study procedures.
7. Current unstable liver disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. NOTE: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) is acceptable if participant otherwise meets entry criteria.
8. Other malignancies are excluded, except for malignancy from which the patients have been disease-free for more than 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, prostate cancer or in situ cervical or breast cancer that has undergone potentially curative therapy.
9. Chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) \< 50% of predicted normal. Note that FEV1 testing is required for participants suspected of having COPD and participants must be excluded if FEV1 is \< 50% of predicted normal.
10. Moderate or severe persistent asthma within the past 2 years (see Attachment XX), or uncontrolled asthma of any classification. Note that participants who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate.
11. History of cardiovascular disease including any of the following:
1. History of clinically significant untreated arrhythmias, including clinically significant ECG abnormalities including second degree (Mobitz Type II) or third degree atrioventricular (AV) block.
2. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of screening.
3. Class III or IV heart failure as defined by the New York Heart Association functional classification system.
4. Uncontrolled hypertension.
12. Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to daratumumab
13. Active infection requiring treatment.
14. Presence of hepatitis B surface antigen (HbsAg), or hepatitis B core antibody (HbcAb), at screening or within 3 months prior to first dose of study treatment. Note: presence of Hep B surface antibody positivity as the only serologic marker (HBsAb) indicating previous vaccination will not exclude a participant provided that patient has a known history of prior HBV vaccination Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment. NOTE: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. Hepatitis RNA testing is optional and participants with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing.
15. Pregnant or lactating female
Exclusion Criteria
1. Systemic anti-myeloma therapy within ≤14 days or 5 half-lives, whichever is shorter, or plasmapheresis within 7 days prior to the first dose of study drug
2. Systemic treatment with high dose steroids (equivalent to \>60 mg prednisone daily for ≥4 days) within the past 14 days if administered to treat MM or non- MM disease
3. Evidence of active bleeding
4. Any major surgery within the last 28 days
2. Systemic treatment with high dose steroids (equivalent to \>60 mg prednisone daily for ≥4 days) within the past 14 days if administered to treat MM or non- MM disease
3. Evidence of active bleeding
4. Any major surgery within the last 28 days
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson
INDUSTRY
Sponsor Role
collaborator
University of Maryland, Baltimore
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ashraf Badros, MD
Role: PRINCIPAL_INVESTIGATOR
University of Maryland, Baltimore Greenebaum Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ashraf Badros, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Blade J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020 May;7(5):e370-e380. doi: 10.1016/S2352-3026(20)30070-3. Epub 2020 Mar 23.
Reference Type
BACKGROUND
Mateos M-V, Usmani SZ, Grosicki S, et al. Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba. Blood. 2019;134(Supplement 1):1906. doi:10.1182/blood-2019-122501
Reference Type
BACKGROUND
Usmani SZ, Mateos M-V, Nahi H, et al. Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update. Blood. 2019;134(Supplement 1):1865. doi:10.1182/blood-2019- 122765
Reference Type
BACKGROUND
Zou P, Wang F, Wang J, Lu Y, Tran D, Seo SK. Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins. J Control Release. 2021 Aug 10;336:310-321. doi: 10.1016/j.jconrel.2021.06.038. Epub 2021 Jun 26.
Reference Type
BACKGROUND
Reinisch M, Untch M, Mahlberg R, Reimer T, Hitschold T, Marme F, Aydogdu M, Schmatloch S, Luck HJ, Schmidt M, Ladda E, Sinn BV, Klare P, Janni W, Jackisch C, Denkert C, Seiler S, Gohler T, Michel L, Burchardi N, Stickeler E, Rey J, Klutinus N, Mobus V, Loibl S. Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study. Breast. 2022 Dec;66:110-117. doi: 10.1016/j.breast.2022.10.002. Epub 2022 Oct 5.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HP-00113670
Identifier Type: OTHER
Identifier Source: secondary_id
2513GCCC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
NCT07287228
NOT_YET_RECRUITING
PHASE1/PHASE2
A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia
NCT05562882
ACTIVE_NOT_RECRUITING
PHASE2
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
NCT03679624
TERMINATED
PHASE2
An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A
NCT05849740
RECRUITING
PHASE4
A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY
NCT07019545
NOT_YET_RECRUITING
PHASE2
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
NCT03275740
TERMINATED
PHASE1
Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia
NCT05932524
UNKNOWN
PHASE2
Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia
NCT05832216
COMPLETED
PHASE1
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07234019
RECRUITING
PHASE2
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
NCT06838962
RECRUITING
PHASE2
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
NCT04323748
UNKNOWN
PHASE1
Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia
NCT05852847
UNKNOWN
PHASE2
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
NCT07007962
RECRUITING
PHASE3
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
NCT07104565
RECRUITING
PHASE2
Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
NCT00107913
UNKNOWN
PHASE2
Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP
NCT01107951
COMPLETED
PHASE2
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
NCT03755518
TERMINATED
PHASE3
Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura
NCT03830749
COMPLETED
PHASE2
A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia
NCT02094417
COMPLETED
PHASE2
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
NCT00770562
COMPLETED
PHASE3
Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)
NCT02223117
COMPLETED
EARLY_PHASE1
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
NCT02055781
TERMINATED
PHASE3
Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia
NCT05446831
UNKNOWN
PHASE2
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
NCT03225716
TERMINATED
PHASE1
Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia
NCT02649504
WITHDRAWN
PHASE3